Evogene
EVGN
15 hedge funds and large institutions have $752K invested in Evogene in 2024 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 4 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
7% more funds holding
Funds holding: 14 → 15 (+1)
4.37% less ownership
Funds ownership: 10.29% → 5.92% (-4.4%)
56% less capital invested
Capital invested by funds: $1.7M → $752K (-$944K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$204K |
| 2 |
Jane Street
New York
|
+$42.1K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$31.3K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$26.4K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$945K |
| 2 |
RIG
Renaissance Investment Group
Lenox,
Massachusetts
|
-$30.7K |
| 3 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
-$11.7K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$890 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$260 |
EVGN Hedge Fund Activity: Q4 2024 in Review
15 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2024, worth a combined $752K — down 56% from $1.7M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new EVGN positions and 4 closed out — a net gain of 1 holder — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, adding an estimated $204K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $945K sold.
- 15 institutional investors held Evogene (EVGN) as of Q4 2024, up from 14 in Q3 2024.
- Funds reported $752K of Evogene stock for Q4 2024, down 56% quarter-over-quarter.
- 5 funds opened new Evogene positions in Q4 2024 and 4 closed out, a net change of +1 holder.
- The largest Evogene buyer in Q4 2024 was Armistice Capital, an estimated $204K added.
- The largest Evogene seller in Q4 2024 was Silverarc Capital Management, an estimated $945K sold.
Based on aggregated 13F filings for Q4 2024.